Lenalidomida

The approval of lenalidomide for the treatment of Multiple Myeloma was based on the results of powerful clinical trials, and constitutes an important step in the approach of patients with relapsed/refractory (rrMM) disease. This paper reports the real life experience of a tertiary cancer center with this drug in rrMM. The overall response rate was 68 % and the median duration of response was 13.6 months. When lenalidomide is used in second line rather than later, quality of response is better, which is associated to longer disease-free and overall survivals.

A aprovação da lenalidomida para tratamento do Mieloma Múltiplo assenta em resultados de ensaios clínicos robustos e constitui um marco importante na abordagem dos doentes com mieloma recaído ou refractário (rrMM). No presente artigo, é reportada a experiência de uso deste fármaco em contexto de vida real no Instituto Português de Oncologia de Lisboa, onde foram tratados 90 doentes em 5 anos. Observou-se resposta clínica em 68% dos casos, com uma duração mediana de 13,6 meses.